Atıf İçin Kopyala
Diniz G., Aktas S., Ortac R., Tunakan M., Unlu I., Vergin C.
PATHOLOGY RESEARCH AND PRACTICE, cilt.202, sa.9, ss.671-677, 2006 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
202
Sayı:
9
-
Basım Tarihi:
2006
-
Doi Numarası:
10.1016/j.prp.2006.04.007
-
Dergi Adı:
PATHOLOGY RESEARCH AND PRACTICE
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Sayfa Sayıları:
ss.671-677
-
Anahtar Kelimeler:
KIT expression, STI-571, spindle cell rhabdomyosarcoma, tumorigenesis, SOFT-TISSUE SARCOMAS, OF-THE-LITERATURE, C-KIT, INHIBITS PROLIFERATION, IMATINIB MESYLATE, INDUCED APOPTOSIS, IN-VITRO, TUMORS, RECEPTOR, LUNG
-
Dokuz Eylül Üniversitesi Adresli:
Hayır
Özet
The use of a relatively nontoxic tyrosine kinase receptor inhibitor, imatimb mesylate (IM) (STI-571), has increasingly become a valuable therapeutic alternative in some KIT (CD117)-overexpressing neoplasms potentially because of the presence of KIT-activating mutations. As the treatment eligibility for this drug hinges on CD117 expression. KIT immunostaining has recently been widely examined in various different tumors.